Cabaletta Bio, Inc. (CABA)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
CABA price, last 12 months
Key stats
- Previous close
- $2.16
- Open
- $2.17
- Day range
- $2.05 – $2.17
- 52-week range
- $2.00 – $4.23
- Volume
- 3.1M
- Avg volume (20 days)
- 6.1M
- Market cap
- $351.0M
Performance
Technicals and fundamentals
About Cabaletta Bio, Inc.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $351.0M